Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.98 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.79 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.79 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.79 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.79 |
| ▸ | MTOR | P42345 | 2/20 | 0.79 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.79 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.79 |
| ▸ | CHUK | O15111 | 1/20 | 0.79 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.79 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.79 |
| ▸ | RAF1 | P04049 | 1/20 | 0.79 |
| ▸ | BRAF | P15056 | 1/20 | 0.79 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.79 |
| ▸ | JAK1 | P23458 | 1/20 | 0.79 |
| ▸ | TYK2 | P29597 | 1/20 | 0.79 |
| ▸ | FLT3 | P36888 | 1/20 | 0.79 |
| ▸ | CLK1 | P49759 | 1/20 | 0.79 |
| ▸ | CLK2 | P49760 | 1/20 | 0.79 |
| ▸ | CLK3 | P49761 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038234 | 1.00 | PIK3CA (0.98) | PIK3CAPIK3CGPIK3C2BPIK3CBPIK3R1 | |
| SCHEMBL258277 | 0.89 | PIK3CA (0.82) | PIK3CAPIK3CGPIK3C2BPIK3CBPIK3R1 | |
| Pi-103 SCHEMBL29352781 | 0.88 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3C2BPIK3CBPIK3R1 | |
| Pi-103 SCHEMBL29929906 | 0.88 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3C2BPIK3CBPIK3R1 | |
| Pi-103 SCHEMBL29676244 | 0.88 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3C2BPIK3CBPIK3R1 | |
| SCHEMBL12922264 | 0.88 | PIK3CA (0.79) | PIK3CAPIK3CGPIK3C2BPIK3CBPIK3R1 | |
| Pi-103 SCHEMBL30387212 | 0.88 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3C2BPIK3CBPIK3R1 | |
| SCHEMBL10122925 | 0.88 | PIK3CA (0.79) | PIK3CAPIK3CGPIK3C2BPIK3CBPIK3R1 | |
| Pi-103 SCHEMBL258242 | 0.88 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3C2BPIK3CBPIK3R1 | |
| SCHEMBL10112597 | 0.88 | PIK3CA (0.79) | PIK3CAPIK3CGPIK3C2BPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| EP-2959014-B1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | GENENTECH INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-9994913-B2 | Methods and compositions for detecting and treating drug resistant AKT mutant | GENENTECH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994913-B2 | Methods and compositions for detecting and treating drug resistant AKT mutant | GENENTECH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20160153049-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | GENENTECH, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160153049-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | GENENTECH, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2014130923-A2 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | GENENTECH, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20130059859-A1 | PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059859-A1 | PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2012088254-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160153049-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | PIK3CA, PIK3C2B, PIK3CG | PIK3CA 1/4885PIK3CG 3/4885PIK3C2B 2/4885 |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | PIK3CA 720/4885PIK3CG 2595/4885PIK3C2B 2544/4885 |
| US-20130059859-A1 | PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | PIK3R2, PIK3R1, AKT2 | PIK3CA 12/4885PIK3CG 40/4885PIK3C2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.